Observe Medical (OBSRV) investor relations material

Strategic vision and market positioning

• Aims to be a leading Nordic MedTech platform with global reach, focusing on scalable, profitable growth and effective manufacturing, leveraging proprietary products and partnerships in the Nordic innovation ecosystem.

• Owns full trademarks and acts as legal manufacturer, ensuring quality and regulatory control.

• Focuses on patient welfare, health economics, and data accuracy as core values.

• Seeks to be a global leader in its category, targeting a top-three position for profitability and efficiency.

Product portfolio and innovation

• UnoMeter Safeti Max is the first new product in its category in 20 years, featuring patented infection control technology and CE certification, now distributed in 46 countries via nearly 30 distributors.

• Product portfolio expanded from 3 to 7 products, increasing addressable market value from NOK 670 million to NOK 2.6 billion.

• Sippi platform expected to further expand market value to over NOK 5 billion with full implementation.

• Product features include a 14-day usage time (double the market standard) and patented UnoSafeCoat technology, with three patents granted and one pending.

• Clinical data supporting Safeti Max has been peer-reviewed, accepted for publication, and presented at major international conferences.

Financial and trading update

• H1 2026 order intake estimated at 10,660, up 73% from H2 2025; H1 2026 sales estimated at 14,378, up 92%.

• Market penetration and portfolio expansion are driving strong growth in both order intake and sales.

• Distributors in 28 countries have placed orders for UnoMeter Safeti Max, with first deliveries starting late June 2026 and high-volume deliveries from September.

• Significant progress in India, a key growth market, with three recent orders and strong brand position.